$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss:- How weight-loss drugs actually work, and how big-name prescriptions differ from each other.- What investors need to know about Ozempic and Mounjarno’s patent cliffs.- The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued.Companies discussed: LLY, NOVO, HIMS, PFE, RHHBY, VKTX, GPCR, ISRG Host: Ricky MulveyGuest: Karl ThielProducer: Mary LongEngineer: Rick Engdahl Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices">megaphone.fm/adchoices</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

The State of Weight-Loss Drugs

Motley Fool Money

AI Chapters

AI Insights

Reviews